regression model was fit to predict the presence of teratoma in the retroperitoneum. The interaction between percentage of teratoma in the orchiectomy and residual RP mass size was assessed in a second logistic model. RESULTS: A total of 422 men were included in the study. Presence of yolk sac tumor in the orchiectomy (OR 3.64, p<0.001), residual mass size (OR 1.19, p<0.001) and percent teratoma in orchiectomy (OR 1.02, p<0.001) were predictors of teratoma in the retroperitoneum. The interaction between RP mass size and percent teratoma in the orchiectomy predicts for the probability of teratoma in the retroperitoneum (Figure 1 ). For patients with no teratoma in the orchiectomy specimen, the probability of teratoma in the retroperitoneum ranges from 40% for small RP masses to >80% for mass over 10cm. In RP masses <2cm, the probability of finding teratoma in the RP ranges from 40% to 80% depending on the percentage of teratoma in the orchiectomy. For RP masses greater than 15cm, the pathology is highly probable to be teratoma irrespectively of teratoma in the testicle.
INTRODUCTION AND OBJECTIVES: Metastatic nonseminomatous testicular germ cell tumor patients with residual retroperitoneal lesions >1cm are treated with postchemotherapy retroperitoneal lymph node dissection (pcRPLND) according to guideline recommendations. However, up to 50% of patients are overtreated since the histology shows residual necrosis/fibrosis only and patients might have been subjected to active surveillance. The aim of our study is to validate and evaluate the two currently best performing prediction models (Vergouwe and Leao) for postchemotherapy residual mass histology.
METHODS: We performed a retrospective analysis including 402 patients who underwent a pcRPLND from 2008 to 2015. This cohort was used to validate the two prediction models by Vergouwe and Leao. Clinical usefulness to predict histology was tested using thresholds as recommended by the original publications.
RESULTS: Using our validation cohort, the Vergouwe model reached a significantly better AUC compared to the Leao model (0.760 , p [ 0.002) in the prediction of benign histology (necrosis/fibrosis). However, adjusting our data to the models had no significant improvement. At a threshold of >70%, the Leao model revealed that pcRPLND would be avoided in 10.2% of patients with benign disease with an error rate of 3.8% for viable tumor, while the Vergouwe model showed an error rate of 10.1% for viable tumor and 2.9% to for teratoma to avoid pcRPLND in 27.4% of all patients with benign disease.
CONCLUSIONS: Our study represents the largest external validation study of the currently best performing prediction models to predict benign histology with a contemporary patient cohort. According to the present study, the discriminatory accuracy of both models is not sufficient to safely select patients for surveillance strategy instead of pcRPLND. Therefore, further studies including new biomarkers such as miRNA 371-3p are needed to optimize the clinical accuracy of potential prediction models and to minimize pcRPLND overtreatment. Traditionally a post chemotherapy retroperitoneal lymph node dissection (pcRPLND) has been advocated as >45% will harbor mature teratoma and 10% viable cancer. However pcRPLND is not without morbidity. The aim of this study is to report the experience of surveillance for 1cm post chemotherapy residual masses.
METHODS: A retrospective review was performed of a prospectively maintained multidisciplinary testicular cancer database at the Princess Margaret Cancer Center. All patients who underwent primary chemotherapy for NSGCT were identified between 1981 and 2018. Patients were classified as having a complete response if there was 1cm residual mass noted on cross sectional imaging with normal serum tumor markers following chemotherapy.
RESULTS: During the study period, 169 men had a complete response ( 1cm residual mass) following chemotherapy. The mean age at initiation of chemotherapy was 29.4 years (Range 15-69 years). The mean follow up was 99.2 months (Range 3-350 months). The AJCC stage at diagnosis included 2A (89-52.7%), 2C (4-2.4%), 3A (37-21.9%), 3b (33-19.5%), 3C (6-3.5%). The IGCCCG risk group classifications were-132 (78.1%) good risk, 31 (18.3%) intermediate risk, 6 (3.5%) poor risk. Of these, 156 men (91.2%) never relapsed and remain disease free. 13 men (7.7%) relapsed after a mean of 72 months (Range 3-339). 8 of these underwent a post chemotherapy RPLND-all are free of disease and alive. The histology of the pcRPLND in these patients was mature teratoma in 6, necrosis in 1 and viable tumor in 1. 5 patients developed disseminated metastases and were treated with salvage chemotherapy. 2 of these have died-two with thoracic metastases.
CONCLUSIONS: Surveillance is a safe strategy for men with residual ( 1cm) masses post chemotherapy and avoids the morbidity associated with pcRPLND. pcRPLND can still be used effectively as a salvage strategy in men who progress.
